1. AB0338 Evaluation of tocilizumab treatment continuation rate stratified by time of start of administration. (23rd January 2014) Authors: Yabe, Y.; Kojima, T.; Kaneko, A.; Kanayama, Y.; Hirano, Y.; Shioura, T.; Saito, K.; Asai, N.; Kobayakawa, T.; Ishiguro, N. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A890 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0443 Influence of the Reason for Discontinuation of Previous TNF Antagonists on the Retention of Tocilizumab. (10th June 2014) Authors: Asai, N.; Kojima, T.; Kaneko, A.; Yabe, Y.; Shioura, T.; Saito, K.; Kobayakawa, T.; Ishiguro, N. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 954 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan. (9th June 2015) Authors: Kojima, T.; Takahashi, N.; Kaneko, A.; Kida, D.; Hirano, Y.; Fujibayashi, T.; Yabe, Y.; Takagi, H.; Oguchi, T.; Miyake, H.; Kato, T.; Watanabe, T.; Hayashi, M.; Shioura, T.; Kanayama, Y.; Funahashi, K.; Asai, S.; Yoshioka, Y.; Terabe, K.; Takemoto, T. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1059 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0564 Continuation and remission rates of tocilizumab treatment based on improvement in patient global assessment: 2-year study based on the tsurumai biologics communication registry. (23rd January 2014) Authors: Asai, N.; Kobayakawa, T.; Saito, K.; Shioura, T.; Yabe, Y.; Kojima, T.; Kaneko, A.; Ishiguro, N. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry. (23rd January 2014) Authors: Yabe, Y.; Kojima, T.; Kaneko, A.; Kanayama, Y.; Shioura, T.; Asai, N.; Kobayakawa, T.; Saito, K.; Ishiguro, N. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification. (23rd January 2014) Authors: Yabe, Y.; Kojima, T.; Kaneko, A.; Kanayama, Y.; Hirano, Y.; Shioura, T.; Saito, K.; Asai, N.; Kobayakawa, T.; Ishiguro, N. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A630 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan. (9th June 2015) Authors: Kojima, T.; Takahashi, N.; Kaneko, A.; Kida, D.; Hirano, Y.; Fujibayashi, T.; Yabe, Y.; Takagi, H.; Oguchi, T.; Miyake, H.; Kato, T.; Watanabe, T.; Hayashi, M.; Shioura, T.; Kanayama, Y.; Funahashi, K.; Asai, S.; Yoshioka, Y.; Terabe, K.; Takemoto, T. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗